<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398953</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3525-II-02</org_study_id>
    <nct_id>NCT04398953</nct_id>
  </id_info>
  <brief_title>A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)</brief_title>
  <official_title>A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with
      relapsed / refractory mantle cell lymphoma (MCL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) assessed by Independent Review Committee (IRC)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) based on investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>up to 12 months</time_frame>
    <description>To assess the changes of genes related to PI3K pathway and bypass in the tissues and / or plasma of enrolled patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Relapsed / Refractory Mantle Cell Lymphoma (MCL)</condition>
  <arm_group>
    <arm_group_label>TQ-B3525 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3525 tablet administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3525</intervention_name>
    <description>TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.</description>
    <arm_group_label>TQ-B3525 tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Understood and signed an informed consent form; 2. Eastern Cooperative Oncology
             Group (ECOG) performance status score of 0 to 2; Life expectancy ≥ 3 months; 3.
             Relapsed / refractory MCL; 4. Has received at least one-line and less than four lines
             of previous treatment, the latest treatment confirmed no objective response, or
             disease progress after treatment; 5. Has at least one measurable lesion; 6. Adequate
             organ system function; 7. Male or female subjects should agree to use an adequate
             method of contraception starting with the first dose of study therapy through 6 months
             after the last dose of study (such as intrauterine devices , contraceptives or
             condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are
             received within 7 days before the first administration.

        Exclusion Criteria:

          -  1. Has central nervous system violation; 2. Has received other PI3K inhibitors; 3. Has
             diagnosed and/or treated additional malignancy within 3 years prior to the first
             administration; 4. Has history of interstitial lung disease; 5. Has a history of
             immunodeficiency diseases; 6. Has multiple factors affecting oral medication; 7. Has
             adverse events caused by previous therapy except alopecia that did not recover to
             ≤grade 1; 8. Has received systemic steroid treatment within 7 days before the first
             administration; 9. Has received other systemic anti-tumor medications within 4 weeks
             before the first administration, or still within the 5 half-life of the medication,
             which occurs first; 10. Has palliative radiation therapy within 4 weeks before the
             first administration; 11. Has active infections within 4 weeks before the first
             administration; 12. Has received surgery, or unhealed wounds within 4 weeks before the
             first administration; 13. Has a history of autologous hematopoietic stem cell
             transplant within 6 months or allogeneic hematopoietic stem cell transplant; 14. QTCF
             &gt; 480ms, LVEF &lt; 50%; 15. Urinary protein ≥ 2 +, and urinary protein quantity ＞1.0 g in
             24 hours within 7 days; 16. Has active hepatitis B or C; 17. Has psychotropic
             substances abuse or a mental disorder; 18. Has other conditions that make it
             inappropriate for the patient to be enrolled based on investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jifeng Feng</last_name>
    <email>fjif@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kaiyang Ding</last_name>
      <email>dingkaiy@126.com</email>
    </contact>
    <investigator>
      <last_name>Kaiyang Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruiyang Xia</last_name>
      <email>xrx2041@163.com</email>
    </contact>
    <investigator>
      <last_name>Ruiyang Xia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Boren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kai Hu</last_name>
      <email>xiaohu7079@sina.com</email>
    </contact>
    <investigator>
      <last_name>Kai Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weijing Zhang</last_name>
      <email>zhangwj3072@163.com</email>
    </contact>
    <investigator>
      <last_name>Weijing Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuankai Shi</last_name>
      <email>syuankaipumc@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuankai Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hang Su</last_name>
      <email>suhang307@126.com</email>
    </contact>
    <investigator>
      <last_name>Hang Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongmei Jing</last_name>
      <email>bysyjhm@sina.com</email>
    </contact>
    <investigator>
      <last_name>Hongmei Jing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yu Yang</last_name>
      <email>yangyu901@163.com</email>
    </contact>
    <investigator>
      <last_name>Yu Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated to Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianda Hu</last_name>
      <email>drjiandahu@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianda Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bing Xu</last_name>
      <email>xubingzhangjian@126.com</email>
    </contact>
    <investigator>
      <last_name>Bing Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chongyang Wu</last_name>
      <email>wuchy@lzu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Chongyang Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenyu Li</last_name>
      <email>liwy1206@163.com</email>
    </contact>
    <investigator>
      <last_name>Wenyu Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingqing Cai</last_name>
      <email>914052383@qq.com</email>
    </contact>
    <investigator>
      <last_name>Qingqing Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hong Cen</last_name>
      <email>cen_hong@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Cen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lihong Liu</last_name>
    </contact>
    <investigator>
      <last_name>Lihong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yufu Li</last_name>
      <email>liyufu439@126.com</email>
    </contact>
    <investigator>
      <last_name>Yufu Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lei Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Lei Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hui Zhou</last_name>
      <email>Zhouhui@126.com</email>
    </contact>
    <investigator>
      <last_name>Hui Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huai'an first people's Hospital</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunling Wang</last_name>
      <email>wcl6506@163.com</email>
    </contact>
    <investigator>
      <last_name>Chunling Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jifeng Feng</last_name>
      <email>fjif@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Jifeng Feng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bing Chen</last_name>
      <email>chenbing2004@126.com</email>
    </contact>
    <investigator>
      <last_name>Bing Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantong Cancer Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaohong Xu</last_name>
      <email>xhx107@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaohong Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhengming Jin</last_name>
      <email>jinzhengming519519@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhengming Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuerong Shuang</last_name>
      <email>shuangyr63@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuerong Shuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sujun Gao</last_name>
      <email>sujung1963@163.com</email>
    </contact>
    <investigator>
      <last_name>Sujun Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Zhongshan Hospital of Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Meiyun Fang</last_name>
      <email>fangmeiyun@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Meiyun Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yajie Gao</last_name>
      <email>gaoyajie100@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Yajie Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Zhang</last_name>
      <email>1592855479@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yang Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Binzhou Medical College</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenzheng Yu</last_name>
      <email>bzywz2009@163.com</email>
    </contact>
    <investigator>
      <last_name>Wenzheng Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingdao Central Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ling Wang</last_name>
      <email>wldoctor@126.com</email>
    </contact>
    <investigator>
      <last_name>Ling Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xuehong Ran</last_name>
      <email>ranxuehong1967@163.com</email>
    </contact>
    <investigator>
      <last_name>Xuehong Ran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weihai Central Hospital</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Binghua Wang</last_name>
    </contact>
    <investigator>
      <last_name>Binghua Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiuzhi Deng</last_name>
    </contact>
    <investigator>
      <last_name>Xiuzhi Deng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bing Xiu</last_name>
      <email>xiubing1233@tongji.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Bing Xiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Wang</last_name>
    </contact>
    <investigator>
      <last_name>Yi Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shuhua Yi</last_name>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Shuhua Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lihua Qiu</last_name>
      <email>JZXQLH@163.com</email>
    </contact>
    <investigator>
      <last_name>Lihua Qiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Rong Fu</last_name>
      <email>florai@sina.com</email>
    </contact>
    <investigator>
      <last_name>Rong Fu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjing People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huaqing Wang</last_name>
      <email>huaqingw@163.com</email>
    </contact>
    <investigator>
      <last_name>Huaqing Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

